gastroesophageal reflux
Conditions
Interventions
experimental group:1-8 weeks: Rabeprazole and probiotics
9-12 weeks: probiotics
control group:1-8 weeks: Rabeprazole and probiotics placebo
9-12 weeks: probioics placebo
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. The following conditions satisfy one of them (1) Esophagitis was detected by gastroscopy in domestic tertiary hospitals within the past 3 months (2) Esophagitis wasnt detected by gastroscopy in domestic tertiary hospitals within the past 3 months, but patients have Symptoms of heartburn, acid reflux, and posterior sternal burning, etc., and the score of Reflux diagnostic questionnaire is >= 12; 2. Age is from 18 to 65 years; both male or female can be included; 3. Sign informed Consent.
Exclusion criteria
Exclusion criteria: 1. In the recent two weeks, patients took gastroesophageal reflux disease treatment drugs (including acid inhibitors, antacids, power promoting drugs, gastric mucosa protective agents and Traditional Chinese medicine, etc.), probiotics and probiotic-related preparations. 2. Complicated with any of the following symptoms or diseases: (1) Hepatic insufficiency, which is defined as aminotransferase (AST) greater than 2 x ULN (upper limit of normal value); (2) Renal insufficiency, defined as serum creatinine (Scr) > ULN; (3) Patients with heart failure and abnormal electrocardiogram; 3. Gastroscopy in domestic tertiary or higher hospitals revealed any of the following diseases within the last 2 months: peptic ulcer, bleeding, gastritis, esophageal and gastric varices, upper gastrointestinal malignant lesions; 4. Patients with myocardial infarction, stroke or malignant tumor; 5. A history of gastroesophageal or duodenal surgery; 6. Recent preparing for pregnancy (including male and female), pregnant or lactating women; 7. Uncooperative patients, such as unwilling to provide personal information, cannot understand informed consent; 8. Allergic to study drugs (rabeprazole) or probiotics. 9. Esophagitis caused by gastric retention and pyloric obstruction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the score of Reflux diagnostic questionnaire; | — |
Secondary
| Measure | Time frame |
|---|---|
| gut microbiota analysis: Intestinal flora diversity;the score of Gastrointestinal Symptom Rating Scale questionnaire;Fecal metabolomics analysis: differences in fecal metabolites and metabolic pathways;body mass index;Changes in grading of esophagitis; | — |
Countries
China
Contacts
Public ContactLyu Nonghua
The First Affiliated Hospital of Nanchang University
Outcome results
None listed